Payment overview · 2025
General Payments
$1,340.37
70 reported records · 14 companies
Healthcare provider profile · identity verified
Christopher Brian Espana, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1003922634
Verified facts
What the public records show
CMS Open Payments records show Christopher Brian Espana, M.D. received $1,340.37 in general payments during 2025 across 70 reported records.
Novo Nordisk Inc accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Jardiance, Mounjaro, Ozempic, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $262.34 | 19.6% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $222.25 | 16.6% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $154.80 | 11.6% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $142.63 | 10.6% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $114.01 | 8.5% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $76.58 | 5.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.58 | 5.4% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $59.08 | 4.4% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $58.07 | 4.3% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $53.09 | 4.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.33 | 3.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $37.04 | 2.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.17 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.40 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,340.37 | 70 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $188.43 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $129.44 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $91.42 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $75.43 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $73.91 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $72.58 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $72.58 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $59.75 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $59.08 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $58.07 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $57.48 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.65 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $55.21 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $53.09 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $53.05 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.73 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $46.15 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $45.33 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $44.01 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $37.04 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $32.05 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.31 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.43 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.43 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.72 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 21 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 151 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 85 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
151 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
49 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 692 | 203 |
| Amlodipine Besylate | Amlodipine Besylate | 571 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 473 | 109 |
| Lisinopril | Lisinopril | 444 | 121 |
| Omeprazole | Omeprazole | 364 | 118 |
| Losartan Potassium | Losartan Potassium | 297 | 91 |
| Metformin Hcl | Metformin Hcl | 266 | 78 |
| Alprazolam | Alprazolam | 263 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 258 | 78 |
| Furosemide | Furosemide | 242 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 70 |
| Gabapentin | Gabapentin | 220 | 67 |
| Sertraline Hcl | Sertraline Hcl | 202 | 62 |
| Enalapril Maleate | Enalapril Maleate | 194 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 185 | 51 |
| Trazodone Hcl | Trazodone Hcl | 183 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 174 | 54 |
| Finasteride | Finasteride | 163 | 45 |
| Meloxicam | Meloxicam | 159 | 56 |
| Eliquis | Apixaban | 151 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 45 |
| Carvedilol | Carvedilol | 147 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 145 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 36 |
| Tramadol Hcl | Tramadol Hcl | 142 | 50 |
| Warfarin Sodium | Warfarin Sodium | 141 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 133 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 47 |
| Simvastatin | Simvastatin | 128 | 35 |
| Allopurinol | Allopurinol | 114 | 31 |
| Memantine Hcl | Memantine Hcl | 107 | 29 |
| Glipizide | Glipizide | 106 | 29 |
| Folic Acid | Folic Acid | 103 | 28 |
| Azithromycin | Azithromycin | 102 | 90 |
| Lovastatin | Lovastatin | 94 | 26 |
| Potassium Chloride | Potassium Chloride | 94 | 31 |
| Alendronate Sodium | Alendronate Sodium | 90 | 28 |
| Prednisone | Prednisone | 89 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 24 |
| Buspirone Hcl | Buspirone Hcl | 86 | 23 |
| Ozempic | Semaglutide | 85 | 16 |
| Celecoxib | Celecoxib | 84 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 79 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | 12 |
| Lorazepam | Lorazepam | 73 | 21 |
| Mirtazapine | Mirtazapine | 72 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 68 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 32 |
| Meclizine Hcl | Meclizine Hcl | 63 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 14 |
| Montelukast Sodium | Montelukast Sodium | 60 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 18 |
| Pregabalin | Pregabalin | 57 | 12 |
| Spironolactone | Spironolactone | 56 | 17 |
| Famotidine | Famotidine | 55 | 14 |
| Olanzapine | Olanzapine | 55 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 40 |
| Bupropion Xl | Bupropion Hcl | 50 | 16 |
| Methylprednisolone | Methylprednisolone | 49 | 45 |
| Paxlovid | Nirmatrelvir/Ritonavir | 49 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 16 |
| Ezetimibe | Ezetimibe | 47 | 12 |
| Glipizide Er | Glipizide | 47 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 45 | suppressed |
| Atenolol | Atenolol | 43 | 15 |
| Amoxicillin | Amoxicillin | 42 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Cephalexin | Cephalexin | 39 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 12 |
| Temazepam | Temazepam | 37 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Naproxen | Naproxen | 36 | 15 |
| Methocarbamol | Methocarbamol | 35 | 13 |
| Torsemide | Torsemide | 35 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 25 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 13 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Acetazolamide | Acetazolamide | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Glyburide | Glyburide | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Semglee (Yfgn) | Insulin Glargine-Yfgn | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | 14 |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,340.37 · 70 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, KISUNLA, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error